Solangepras

CVN424 is an orally active and selective GPR6 inverse agonist with a Ki of 9.4 nM and an EC50 of 38 nM. CVN424 is brain-penetrant and has the potential for Parkinson disease research[1][2].

Product Specifications

CAS Number

[2254706-21-1]

Product Name Alternative

CVN424

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

GPR6

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/cvn424.html

Purity

99.70

Solubility

DMSO : 58.33 mg/mL (ultrasonic)

Smiles

FC1=C(OC2CCN(C3=NC4=C(N=C3N[C@H]5COCC5)CN(CC4)C(C)=O)CC2)C=CC(F)=C1

Molecular Formula

C24H29F2N5O3

Molecular Weight

473.52

Precautions

H315, H319, H335

References & Citations

[1]Huikai Sun, et al. First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate. J Med Chem. 2021 Apr 16.|[2]Nicola L Brice, et al. Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. J Pharmacol Exp Ther. 2021 Jun;377 (3) :407-416.